About Bioatla (BCAB)
BioAtla, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
- USD0.81
- USD0.82
- USD0.59
- USD1.43
- -20.70%
- --
- 6.16M
- 1.87M
- 49M
- 0.24
- 21.50%
Stock News
1 hour ago
Is the Times Square New Year’s Eve ball drop on your bucket list? Here’s why life goals like that aren’t worth the time or money.
MarketWatch
2 hours ago
Op-ed: China won the 2025 battle in Trump's trade war. Here's what comes next
CNBC
3 hours ago
The Club's top 10 things to watch in the stock market Wednesday
CNBC
3 hours ago
27-year-old quit her 9-to-5 to start a floral business—this year, she brought in 6 figures and designed bouquets for Sabrina Carpenter, Katy Perry
CNBC